Opinion|Videos|July 22, 2024
Recent Data on Bimekizumab for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps
2
$20 Billion National Strategy Aims to Close the Women's Health Gap
3
GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH
4
Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women
5